1. Home
  2. EXAS vs JEF Comparison

EXAS vs JEF Comparison

Compare EXAS & JEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXAS
  • JEF
  • Stock Information
  • Founded
  • EXAS 1995
  • JEF 1968
  • Country
  • EXAS United States
  • JEF United States
  • Employees
  • EXAS N/A
  • JEF N/A
  • Industry
  • EXAS Medical Specialities
  • JEF Investment Bankers/Brokers/Service
  • Sector
  • EXAS Health Care
  • JEF Finance
  • Exchange
  • EXAS Nasdaq
  • JEF Nasdaq
  • Market Cap
  • EXAS 10.7B
  • JEF 11.0B
  • IPO Year
  • EXAS N/A
  • JEF N/A
  • Fundamental
  • Price
  • EXAS $53.02
  • JEF $52.87
  • Analyst Decision
  • EXAS Strong Buy
  • JEF Buy
  • Analyst Count
  • EXAS 20
  • JEF 4
  • Target Price
  • EXAS $70.68
  • JEF $56.67
  • AVG Volume (30 Days)
  • EXAS 2.9M
  • JEF 1.7M
  • Earning Date
  • EXAS 07-30-2025
  • JEF 06-30-2025
  • Dividend Yield
  • EXAS N/A
  • JEF 3.01%
  • EPS Growth
  • EXAS N/A
  • JEF 144.59
  • EPS
  • EXAS N/A
  • JEF 2.90
  • Revenue
  • EXAS $2,828,128,000.00
  • JEF $6,865,419,000.00
  • Revenue This Year
  • EXAS $14.58
  • JEF N/A
  • Revenue Next Year
  • EXAS $12.75
  • JEF $14.89
  • P/E Ratio
  • EXAS N/A
  • JEF $18.30
  • Revenue Growth
  • EXAS 11.57
  • JEF 33.18
  • 52 Week Low
  • EXAS $39.97
  • JEF $39.28
  • 52 Week High
  • EXAS $72.83
  • JEF $82.68
  • Technical
  • Relative Strength Index (RSI)
  • EXAS 45.95
  • JEF 55.80
  • Support Level
  • EXAS $51.50
  • JEF $52.52
  • Resistance Level
  • EXAS $53.30
  • JEF $53.95
  • Average True Range (ATR)
  • EXAS 1.62
  • JEF 1.37
  • MACD
  • EXAS -0.64
  • JEF 0.16
  • Stochastic Oscillator
  • EXAS 26.95
  • JEF 79.02

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

About JEF Jefferies Financial Group Inc.

Jefferies Financial Group Inc is a full-service investment banking and capital markets firm. It has two reportable segments; Investment Banking and Capital Markets which is also the majority revenue generating segment, includes securities, commodities, corporate lending, futures and foreign exchange capital markets activities and its investment banking business, which provides underwriting and financial advisory services to clients across different sectors. The Asset Management reportable business segment provides alternative investment management services to investors in the U.S. and overseas and generates investment income from capital invested in and managed by it or its affiliated asset managers. Operates geographically in America, Europe and Middle East, Asia Pasific.

Share on Social Networks: